It is said that only God and a few good men and women run India. One such man is P H Kurien. For readers unfamiliar with his name, Kurien was India's Controller General of Patents, Designs & Trade Marks until March 12, 2012. On March 9, 2012, just three days before he left office, he issued the first-ever compulsory licence in India for the manufacture of a drug still under patent....

-The Indian Express Drug regulation is a mess. Everyone who propped up this irresponsible system is to blame Last week, a parliamentary standing committee on health delivered a thoroughly damaging report on the state of drug regulation in India, and the collusion between the regulator, industry and the medical profession that puts patients last. Over 118 pages, it said that the Drug Controller General of India (DCGI) and the Drug Standards Control...

Health activists from across the country have asked the Union Health and Family Welfare Ministry to take immediate cognisance of the recent report of the Department Related Standing Committee that has criticised the functioning of the Central Drugs Standard Control Organisation (CDSCO) for irregular approvals for clinical trials and sale of medicines to pharmaceutical companies that put patients at risk. In a statement issued here on Wednesday, the activists asked the...

The proposed criminalisation of consensual sex between youngsters in the 16-18 age group is seen as regressive and in denial of social realities. THE minimum age for consensual sex has been raised from 16 to 18 in the amended Protection of Children from Sexual Offences Bill, 2011, recently approved by the Union Cabinet. If approved by Parliament, this will make sexual activity with a person below 18 a criminal offence,...

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented Drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...